Tandem reassembly of split luciferase-DNA chimeras for bioluminescent detection of attomolar circulating microRNAs using a smartphone

2021 ◽  
Vol 173 ◽  
pp. 112824 ◽  
Author(s):  
Lanlan Zhou ◽  
Linling Zhang ◽  
Liu Yang ◽  
Wei Ni ◽  
Yong Li ◽  
...  
2017 ◽  
Author(s):  
Elena Valassi ◽  
Natalia Garcia-Giralt ◽  
Jorge Malouf ◽  
Iris Crespo ◽  
Susan M. Webb

2019 ◽  
Author(s):  
Jelena Jankovic-Miljus ◽  
Leon Wert-Lamas ◽  
Maria Augusta Guillen-Sacoto ◽  
Andrea Martinez-Cano ◽  
Pilar Santisteban ◽  
...  

2021 ◽  
Vol 20 ◽  
pp. 153303382110119
Author(s):  
Wen-Ting Zhang ◽  
Guo-Xun Zhang ◽  
Shuai-Shuai Gao

Background: Leukemia is a common malignant disease in the human blood system. Many researchers have proposed circulating microRNAs as biomarkers for the diagnosis of leukemia. We conducted a meta-analysis to evaluate the diagnostic accuracy of circulating miRNAs in the diagnosis of leukemia. Methods: A comprehensive literature search (updated to October 13, 2020) in PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang database and China National Knowledge Infrastructure (CNKI) was performed to identify eligible studies. The sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) for diagnosing leukemia were pooled for both overall and subgroup analysis. The meta-regression and subgroup analysis were performed to explore heterogeneity and Deeks’ funnel plot was used to assess publication bias. Results: 49 studies from 22 publications with a total of 3,489 leukemia patients and 2,756 healthy controls were included in this meta-analysis. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio and area under the curve were 0.83, 0.92, 10.8, 0.18, 59 and 0.94, respectively. Subgroup analysis shows that the microRNA clusters of plasma type could carry out a better diagnostic accuracy of leukemia patients. In addition, publication bias was not found. Conclusions: Circulating microRNAs can be used as a promising noninvasive biomarker in the early diagnosis of leukemia.


2021 ◽  
Vol 22 (3) ◽  
pp. 1176
Author(s):  
Francesca Precazzini ◽  
Simone Detassis ◽  
Andrea Selenito Imperatori ◽  
Michela Alessandra Denti ◽  
Paola Campomenosi

Studies investigating microRNAs as potential biomarkers for cancer, immune-related diseases, or cardiac pathogenic diseases, among others, have exponentially increased in the last years. In particular, altered expression of specific miRNAs correlates with the occurrence of several diseases, making these molecules potential molecular tools for non-invasive diagnosis, prognosis, and response to therapy. Nonetheless, microRNAs are not in clinical use yet, due to inconsistencies in the literature regarding the specific miRNAs identified as biomarkers for a specific disease, which in turn can be attributed to several reasons, including lack of assay standardization and reproducibility. Technological limitations in circulating microRNAs measurement have been, to date, the biggest challenge for using these molecules in clinical settings. In this review we will discuss pre-analytical, analytical, and post-analytical challenges to address the potential technical biases and patient-related parameters that can have an influence and should be improved to translate miRNA biomarkers to the clinical stage. Moreover, we will describe the currently available methods for circulating miRNA expression profiling and measurement, underlining their advantages and potential pitfalls.


Gene ◽  
2021 ◽  
Vol 768 ◽  
pp. 145334
Author(s):  
Deeba S. Jairajpuri ◽  
Zainab H. Malalla ◽  
Naeema Mahmood ◽  
Farah Khan ◽  
Wassim Y. Almawi

HPB ◽  
2019 ◽  
Vol 21 ◽  
pp. S760
Author(s):  
L. Meijer ◽  
I. Garajová ◽  
C. Caparello ◽  
T. Le Large ◽  
N. Funel ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document